Literature DB >> 3164308

Beneficial effects of imipramine on Tourette's syndrome.

R Sandyk1, C R Bamford.   

Abstract

Gilles de la Tourette's syndrome (GTS) is a chronic neuropsychiatric disorder characterized by multiple involuntary motor and phonic tics associated with behavioural disturbances including obsessive-compulsive and aggressive behavior, depression and, rarely, psychosis. The relationship of GTS, presumed to be predominantly a dopaminergic disorder, and depression, presumed to be a noradrenergic-serotoninergic deficiency state, is currently poorly understood. The reports published to date on the effects of tricyclic antidepressants in GTS have been contradictory; while Messiha et al. (1976) used imipramine successfully in one GTS patient, Abuzzahab and Anderson (1973) and Fras (1978) on the other hand, found imipramine to exacerbate GTS symptoms and cautioned its usage in this syndrome. A more recent report suggested that imipramine is useful in GTS patients who exhibit symptoms of attention deficit disorder (Dillon et al., 1985). We report a patient with GTS whose depression and behaviour improved considerably when low-dose imipramine (Tofranil) was added to the regimen of anti-GTS medication. This report suggest that tricyclic antidepressants may be useful adjuncts in the management of GTS, and hints at norepinephrinergic and serotoninergic deficiencies as being components of the pathogenesis of the syndrome.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3164308     DOI: 10.3109/00207458808985689

Source DB:  PubMed          Journal:  Int J Neurosci        ISSN: 0020-7454            Impact factor:   2.292


  2 in total

1.  Case report: Exacerbation and provocation of tics by imipramine and sulpiride.

Authors:  Christian Eggers; Renate Schepker; Robert Oades
Journal:  Eur Child Adolesc Psychiatry       Date:  1993-07       Impact factor: 4.785

Review 2.  Pharmacological options for the treatment of Tourette's disorder.

Authors:  F J Jiménez-Jiménez; P J García-Ruiz
Journal:  Drugs       Date:  2001       Impact factor: 9.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.